Shanghai Haini Pharmaceutical Co.

What Shanghai Haini Pharmaceutical Co. does

Shanghai Haini Pharmaceutical Co., Ltd. (上海海尼药业有限公司) is a Shanghai-based pharmaceutical manufacturer founded on September 11, 2001 as the first wholly-owned subsidiary of Yangtze River Pharmaceutical Group established outside Taizhou. The company operates from a ~280,000 sqm campus in Zhoupu Town, Pudong New Area, with ~70,000 sqm of built area and a 47% greening rate, employing 300–500+ staff (figures vary by source). Its portfolio covers 20+ product specifications across cardiovascular, circulatory, digestive, and gynecological therapeutic areas, with flagship products including Landi (amlodipine besylate tablets for hypertension), Xuesu (loratadine tablets for allergies), Tian Li, Hutan, and Xingdi. Manufacturing covers both solid dosage forms (tablets, capsules) and liquid preparations under a proprietary "Golden Circle Rule" drug quality risk control framework, Six Sigma management, and Excellence Performance Management, with facilities certified under domestic GMP (since 2002 for solids) and EU GMP (since May 2017 for the solid preparation workshop). Landi was the first Shanghai product to pass generic drug consistency evaluation (March 2018) and Xuesu the first loratadine to pass (April 2019); Xingdi was selected for the 8th national centralized volume-based procurement batch in 2023.

The company sells prescription and generic drugs to hospitals, clinics, and pharmacies across 30+ Chinese provinces, serving hundreds of millions of patients, primarily through enterprise field sales, government tendering, and pharmacy distribution. Over the most recent ~8-year period, cumulative sales reached approximately 12.5 billion CNY with cumulative tax contributions exceeding 2 billion CNY (421 million CNY in 2018 alone). Its GTM motion is enterprise field sales into healthcare providers, supplemented by national volume-based procurement participation (where Xingdi secured a 2023 contract) and OTC pharmacy distribution. Pricing is governed by China's centralized procurement mechanism; specific price points are not publicly disclosed. As a wholly-owned subsidiary of Yangtze River Pharmaceutical Group — ranked #1 among China's top 100 pharmaceutical companies for three consecutive years — Haini operates without independent public ownership or listing, and all strategic direction rests with the parent conglomerate.

Name

Shanghai Haini Pharmaceutical Co.

Legal name

Shanghai Haini Pharmaceutical Co., Ltd.

Website

https://ehaini.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Short description

Shanghai Haini Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Yangtze River Pharmaceutical Group that manufactures prescription and generic drugs (tablets, capsules, injections) across cardiovascular, circulatory, digestive, and gynecological therapeutic areas, selling through hospitals, clinics, and pharmacies across 30+ Chinese provinces.

Ownership category

akta.pro rank

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the manufacture and sale of prescription and generic pharmaceutical products. Product portfolio covers circulatory system drugs, cardiovascular medications, digestive system drugs, and gynecological treatments, with over 20 product specifications. Key products include Landi (amlodipine besylate tablets) and Xuesu (loratadine tablets). Products are sold to hospitals, clinics, and pharmacies across 30+ Chinese provinces, serving hundreds of millions of patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Shanghai Haini Pharmaceutical Co. is a Chinese pharmaceutical manufacturer that develops, produces, and sells Western and traditional Chinese medicines in solid dosage forms (tablets, capsules) and liquid preparations. The company manufactures over 20 product specifications spanning cardiovascular, circulatory, digestive, and gynecological therapeutic areas, with flagship products including Landi (amlodipine besylate tablets) and Xuesu (loratadine tablets). Products are sold to hospitals, clinics, and pharmacies across 30+ Chinese provinces.

Product overview

Shanghai Haini Pharmaceutical Co. is a pharmaceutical manufacturing company that produces both Chinese and Western medicines, offering products across multiple therapeutic areas including circulatory system drugs, cardiovascular medications, digestive system treatments, and gynecological products, comprising more than 20 product specifications. The core products include Landi (Amlodipine Besylate Tablets) for cardiovascular conditions, Xuesu (Loratadine Tablets) for allergies, along with other branded products. The company operates as part of Yangtze River Pharmaceutical Group and maintains GMP-compliant manufacturing facilities with both solid and liquid production workshops.

Differentiator

Problem solved

Functional benefit

Products and services

• Landi (兰迪) — Amlodipine Besylate Tablets (苯磺酸氨氯地平片) Cardiovascular drug (amlodipine besylate tablets) used to treat hypertension and angina. The flagship product of Shanghai Haini Pharmaceutical; a Shanghai Famous Trademark and Shanghai Famous Brand Product sold to hospitals, clinics, and pharmacies across 30+ Chinese provinces.
• Xuesu (雪苏) — Loratadine Tablets (氯雷他定片) Anti-allergic medication (loratadine tablets) used to treat allergic rhinitis and chronic urticaria. A core product of Shanghai Haini Pharmaceutical, sold across China.
• Tian Li (田力) Pharmaceutical product of Shanghai Haini Pharmaceutical Co., recognized as a Shanghai Pharmaceutical Industry Famous Product in 2018 alongside Landi and Hutan.
• Hutan (护坦) Pharmaceutical product of Shanghai Haini Pharmaceutical Co., recognized as a Shanghai Pharmaceutical Industry Famous Product in 2018 alongside Landi and Tian Li.
• Xingdi (星迪) Pharmaceutical product of Shanghai Haini Pharmaceutical Co. selected for the 8th national volume-based centralized procurement in 2023, securing large-volume government contracts.

Quantifiable outcome

• Products sold across 30+ Chinese provinces serving hundreds of millions of patients
• +5 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Shanghai International Medical Park (上海市国际医学园区)minorStrategic or Co-development Partner · 1 January 2017Haini Pharmaceutical is located adjacent to the Shanghai International Medical Park, enabling potential synergies in healthcare innovation, clinical research, and medical services collaboration. The proximity facilitates partnerships with nearby medical institutions and research centers.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Jiangsu Hengrui Pharmaceuticals: One of China's largest innovative and generic pharmaceutical manufacturers with broad therapeutic area coverage and significant R&D investment. Comparable as a Chinese pharma manufacturer selling through hospital channels and participating in national volume-based procurement.
• CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharmaceutical conglomerate with cardiovascular and anti-allergy franchises overlapping Haini's therapeutic focus. Comparable in scale, hospital channel orientation, and generic-plus-innovative product strategy.
• Fosun Pharma: Shanghai-headquartered diversified pharmaceutical and healthcare conglomerate with significant generic manufacturing operations. Comparable as a major Chinese pharma manufacturer with multi-therapeutic-area portfolio and hospital channel focus.
• Yangtze River Pharmaceutical Group: Parent conglomerate and China's #1 ranked pharmaceutical company. Directly comparable as a Chinese generic and branded pharma manufacturer with nationwide distribution, providing a reference point for Haini's positioning within the group's portfolio.
• Sino Biopharmaceutical: Hong Kong-listed Chinese pharmaceutical group with strong cardiovascular, respiratory, and digestive system therapeutic coverage. Comparable in therapeutic area overlap (including cardiovascular generics similar to Landi/amlodipine) and hospital distribution model.

Direct peers

• Qilu Pharmaceutical: Shandong-based Chinese pharmaceutical manufacturer with broad generic portfolio including cardiovascular and anti-allergy categories. Comparable as a privately held (non-listed) Chinese generic manufacturer participating in volume-based procurement.
• Livzon Pharmaceutical Group: Mid-sized Chinese pharmaceutical manufacturer with overlapping therapeutic areas including digestive and cardiovascular products. Comparable in scale, generic manufacturing focus, and channel orientation to public hospitals.
• Zhejiang Huahai Pharmaceutical: Zhejiang-based Chinese pharmaceutical manufacturer specializing in cardiovascular and other generics with strong export business and US/EU regulatory approvals. Comparable in generic cardiovascular focus and GMP-certified export-grade manufacturing capabilities.
• China Grand Pharmaceutical and Healthcare Holdings: Hong Kong-listed Chinese pharmaceutical group with cardiovascular and respiratory therapeutic areas. Comparable as a mid-sized Chinese pharma manufacturer selling through hospital channels and competing in national volume-based procurement.

Regional players

• Shanghai Pharmaceuticals Holding: Shanghai-headquartered state-owned pharmaceutical group combining manufacturing and distribution. Comparable as a Shanghai-based pharma manufacturer with cardiovascular and other generic drug portfolios selling through hospital channels across China.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Haini Pharmaceutical Co.